Bliss GVS Pharma Ltd

₹ 73.6 -0.94%
03 Feb - close price
About

Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.

Key Points

Product Portfolio:
a) Pharma Products:[1]
Capsules, Creams/Gels/Ointments, Dry Powder for Injection and for Oral Suspension, Eye/Ear Drops, Effervescent tablets, Lotions, Injections, Liquid Preparations, Lozenges, Nasal Solutions, Oral Solids, Parenteral, etc.
b) Other Healthcare Products:[2]
Balm, Cream, Lotion, OTC products, Petroleum Jelly, Powder, Roll On
c) Therapeutics:[3]
Analgesic, Antacid, Anti-malarial, Anti-fungal, Anti-bacterial, Anti-biotic, Anti-inflammatory, Anti-diarrheic, anti-diabetic, etc.

  • Market Cap 767 Cr.
  • Current Price 73.6
  • High / Low 96.9 / 66.1
  • Stock P/E 8.80
  • Book Value 82.0
  • Dividend Yield 0.68 %
  • ROCE 14.2 %
  • ROE 3.48 %
  • Face Value 1.00

Pros

  • Stock is trading at 0.90 times its book value

Cons

  • The company has delivered a poor sales growth of -1.31% over past five years.
  • Promoter holding is low: 34.5%
  • Company has a low return on equity of 8.83% over last 3 years.
  • Company has high debtors of 192 days.
  • Promoter holding has decreased over last 3 years: -7.14%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
148 120 130 152 164 132 168 196 216 167 189 172 206
115 104 110 120 126 115 134 167 182 147 150 148 158
Operating Profit 33 16 19 32 38 17 35 29 34 20 39 25 48
OPM % 22% 13% 15% 21% 23% 13% 21% 15% 16% 12% 21% 14% 23%
6 5 7 3 4 6 8 5 -68 12 7 2 6
Interest 1 5 2 0 1 2 1 1 1 2 2 2 1
Depreciation 3 3 4 4 4 4 4 4 4 4 5 5 5
Profit before tax 34 13 20 30 37 17 37 30 -39 26 39 20 47
Tax % 26% 58% 18% 28% 26% 51% 29% 26% -25% 11% 30% 21% 37%
Net Profit 25 6 17 22 28 8 26 22 -49 23 27 16 30
EPS in Rs 2.30 0.85 1.57 1.99 2.48 0.60 2.35 2.05 -4.83 1.89 2.48 1.33 2.68
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 TTM
219 267 397 345 407 547 798 815 899 689 577 747 734
161 196 285 273 304 391 596 618 739 566 471 629 603
Operating Profit 58 71 111 71 103 156 203 197 160 123 107 118 131
OPM % 27% 27% 28% 21% 25% 29% 25% 24% 18% 18% 18% 16% 18%
3 16 14 28 20 24 12 -8 35 26 20 -42 27
Interest 2 4 10 18 16 19 20 23 4 8 6 5 7
Depreciation 5 4 6 11 11 13 20 21 9 13 17 17 18
Profit before tax 53 79 109 71 96 148 175 145 182 129 104 54 133
Tax % 23% 34% 46% 42% 36% 32% 36% 39% 30% 26% 29% 57%
Net Profit 41 53 60 41 61 100 113 89 127 95 74 23 97
EPS in Rs 3.94 5.09 5.60 3.97 5.81 8.00 7.95 5.70 11.99 9.43 6.64 1.45 8.38
Dividend Payout % 15% 15% 12% 13% 12% 6% 8% 18% 8% 5% 8% 34%
Compounded Sales Growth
10 Years: 11%
5 Years: -1%
3 Years: -6%
TTM: 3%
Compounded Profit Growth
10 Years: -6%
5 Years: -19%
3 Years: -39%
TTM: 35%
Stock Price CAGR
10 Years: 7%
5 Years: -17%
3 Years: -19%
1 Year: -23%
Return on Equity
10 Years: 14%
5 Years: 12%
3 Years: 9%
Last Year: 3%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Sep 2022
10 10 10 10 10 10 10 10 10 10 10 10 10
Reserves 156 200 248 277 327 402 476 526 636 725 798 808 843
8 45 148 173 160 132 225 118 102 126 122 109 103
39 54 165 123 166 218 311 206 157 168 147 181 144
Total Liabilities 213 310 571 583 662 762 1,023 860 905 1,030 1,077 1,109 1,101
20 40 168 213 234 225 305 143 146 242 234 281 278
CWIP 8 7 1 4 -0 9 4 0 47 -0 2 22 39
Investments -0 1 0 0 0 0 0 0 0 0 0 2 3
186 262 402 365 428 527 714 717 712 788 840 803 781
Total Assets 213 310 571 583 662 762 1,023 860 905 1,030 1,077 1,109 1,101

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
36 6 41 38 113 289 18 40 47 64 135
-22 -124 -11 -29 -50 -249 48 -79 -40 -45 -103
26 110 -8 -42 -40 -10 -76 17 -6 -21 -24
Net Cash Flow 40 -8 22 -34 23 30 -10 -22 0 -2 9

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Debtor Days 200 176 225 228 222 201 116 134 187 290 293 192
Inventory Days 33 29 58 70 69 55 50 55 46 64 110 116
Days Payable 90 95 212 176 165 153 100 55 47 75 82 86
Cash Conversion Cycle 143 111 71 121 126 102 67 134 186 279 321 221
Working Capital Days 165 135 130 146 160 125 76 182 180 269 319 219
ROCE % 39% 36% 20% 24% 32% 31% 29% 27% 19% 12% 14%

Shareholding Pattern

Numbers in percentages

Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
41.60 41.60 41.60 33.31 33.31 33.24 33.19 33.14 33.14 34.51 34.55 34.46
24.16 23.96 23.37 23.34 22.83 21.24 21.01 19.59 17.33 17.17 16.68 16.53
2.96 2.96 5.73 5.74 6.72 6.72 6.67 6.66 6.66 6.65 6.64 6.63
31.28 31.48 29.31 37.61 37.14 38.80 39.13 40.61 42.87 41.67 42.13 42.35

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls